Abivax reports excellent efficacy and safety of ABX464 in phase 2b clinical trial in ulcerative colitis and plans to proceed to phase 3

Written by Petra Hegmann on 25th May 2021. Posted in Client News.

[image_slider_no_space on_click=”prettyphoto” height=”600″ navigation_style=”light” images=”940,950,954,952,953,951″]